Please note that this conference is being recorded. I will now hand the conference over to Ms. Seema Nayak from ICICI Securities Limited for opening remarks. Thank you, and over to you, Seema. Good morning, ladies and gentlemen. Thank you for joining us today on Q3 FY 2026 Earnings Call of IKS Health. On behalf of ICICI Securities, I would like to thank the management of IKS Health for giving us the opportunity to host this call. Today we have with us Mr. Sachin Gupta, Founder and CEO; Ms. Nithya Balasubramanian, CFO; and Mr. Saransh Mundra, Head of Investor Relations. I turn it over to Mr. Saransh for his brief statement and to take the proceedings forward. Thank you, and over to you, Saransh. Hi. Good morning, everyone. Just a disclaimer before we start: as part of the prepared remarks, we may make certain statements which are forward-looking in nature. We don't take any responsibility to update such forward-looking statements, and your discretion is warranted while making any investment decisions. Over to you, Sachin. Thank you, Saransh, and good morning and good evening, everyone. Welcome to our fifth earnings call. Since we went public in December 2024, our agenda obviously is to talk through our performance for the quarter ending December 31st, 2025, the Q3 fiscal 2026. Before I go into talking about our fifth consecutive quarter of industry-leading performance since we went public, I'd like to take a few minutes to give everybody an update about the business and how we are progressing on the strategic pillars of execution that we have highlighted over the last several conversations. And to kick it off, one of the things that I've been accused of by many on this call and otherwise is that I resort to using too much healthcare jargon in my opening remarks. And so I will continue to try and do my best to not resort to that tendency. And with that backdrop so look, for those that are new to our business, what is our business? Essentially, we are in the business of taking away chore tasks from healthcare providers in the U.S. so that they are not distracted by those chores and focus on their core task of patient care. That's the fundamental business. And believe it or not, those chore tasks that distract healthcare providers in the U.S. from the core task of patient care cost the U.S. healthcare industry somewhere in the range of $260-odd billion, which is the TAM that we are targeting. And it's a highly underpenetrated TAM because most of these tasks today are done by the large healthcare enterprises in-house within their own organizations. However, there is a rising trend to delegate or outsource these tasks to companies like us. And that outsourced market now is about $35 billion and is growing at about 12% a year. We built this business with the idea simply that we will outsource these tasks to the right combination of people and technology. When we started out, we were much more people-centric, which is why, as you've seen, we have nearly 13,350 people across the world, most of which are in India, north of 10,000 are in India. We started in a people-centric model, but we always knew that the solution to scale would be through technology. And so we started with a human-led and tech-in-the-loop. Over the last 10 years, and very specifically over the last five years, we have moved to a much more tech-led and really AI-first, especially over the last couple of three years as generative AI came into play, we've moved to a much more tech-led, AI-first orchestration, which is why, just as an example point, without going into details of numbers, when you look at our growth for the quarter ending December 31st, 2025, which is 24% year-on-year growth, when you look at our headcount growth, it's barely 1%. So it's almost flat headcount relative to 24% year-on-year revenue growth. That, if nothing else, is the true demonstration of how we are truly leveraging AI and technology to sort of break this linearity between revenue growth and people growth, or for that matter, between the impact that we are bringing into the provider organizations and the number of people that we have to continue to deploy to take away these tasks from them. The other hallmark of our business model has always been a much more outcome-based approach. We do not focus with our customers, and they don't have to worry with us as it relates to how much effort it takes us to eliminate those tasks for us. That is our problem to solve, not theirs. We just align, and our customers pay us as a percentage of their revenue. And so in that stripe of structure, it's highly aligned. Our fortunes are highly aligned with their fortunes. Obviously, when we drive more and more tech leverage in our business, that leads to better scalability, better outcomes for our customers. Also, it leads to perhaps some margin protection for us over a period of time. Very simply put, that is the fundamentals of the business, nothing too complex about it. Now, moving on to sort of the key sort of moat of the business, in a market where you have a $260 billion TAM, and we're talking about 16 different tasks. In the by the way, we started our business, and we were predominantly focused for the first 15-odd years on the physician market, which is the outpatient clinic setting, because we believe that healthcare transformation needs to be led by physicians. We started in the outpatient setting. Over a period of time, as the outpatient setting got more and more consolidated and health systems bought a lot of these clinics and started employing the doctors, we have slowly gotten pulled into the health system market as well. Now we are also participating in the hospital part of the TAM. We have a platform that delegates about 16-odd different chore tasks from the physician's workflow in the outpatient setting. And we are slowly building a replica of that platform for the hospital setting, which is an endeavor that we started over the last, say, a couple of three years. Eventually, we hope to have a comprehensive platform that cuts across the continuum of care from ambulatory to acute. Ambulatory, again, sorry for the jargon. Ambulatory in the U.S. obviously means outpatient settings, clinics, and acute is the actual traditional hospital setting. That is sort of a high-level overview of who we are as a business. We have laid out five critical pillars of execution to continue to drive our leadership position in this market. Typically, I tend to report our progress across those five pillars before I get into our financials. Happy to report that this quarter was a quarter of strong execution across those five pillars. The first pillar really is to continue to transform various features of our platform and truly the entire platform from this human-led that we were about five to seven years ago to now a true AI-native agentic platform manifest. And in that regard, we've made progress on several fronts. One is that we've rolled out, you must have seen, an interconnected set of workflows that actually delegate or outsource three fundamental tasks that cause a lot of friction in the patient's journey with the healthcare providers. Are you guys having trouble hearing me? Operator, am I not coming through clearly? I'm hearing some sounds of text messages. Somebody's phone off? Operator, am I coming through clearly? Some people are saying you're not able to hear me clearly. Is that true? Ruchi, operator, anybody? Sir, earlier you were not coming through, sir. Right now, you're coming in loud and clear, sir. Okay. Did we miss a large part of my discourse? Yes, sir. Okay. I'll try to repeat some of it. Sorry about that. I don't know what happened. Please, operator, just call us directly on Saransh's mobile if that happens again. Sure, sir. Okay. Thank you. Okay. So I guess just to sort of quickly repeat the portion about the fundamentals of our business. Like I said, the business model is focused on taking away these chore tasks. And the TAM of these chore tasks is about $260 billion, of which the outsourcing penetration is about $34 billion, growing at about 12%, which basically means that if we are growing faster than 12%, then we are gaining market share in this outsourced TAM. If we are growing slower than 12% annually, we're probably losing market share. And the other thing that I was pointing out, I don't know where I got cut off, is that our model entails leveraging the right combination of technology and human capital to outsource these tasks. And I was highlighting how over the last several years, we've broken that linearity between people growth and revenue growth, which is also exemplified by our latest quarter performance where, as you can see, our headcount as of December 31st, 2025, is about 13,350. Same time last year, it was about 13,150. So you can see there's only a 1.5% growth in headcount for a 24% growth in revenue in rupee terms or a 19% growth in revenue in dollar terms. And so that just, if nothing else, truly demonstrates the power and the leverage of technology in the business and the true leverage that we are being able to drive lately using our generative AI solutions. Moving on, I think. What is that? Are you guys still able to hear me? Yes, sir. We are able to hear you. Please go ahead, sir. Okay. Thank you. All right. So I was starting to talk to the five key pillars of execution that we typically tend to focus on as a business and that we build our discourse around that aligns our execution strategy with hopefully your understanding of our business. The first one, like I was saying, is this moving from human-led to tech-led and really an AI-native agentic platform. We're starting to talk about three tasks amongst those 16 tasks from the physician setting that are ones that cause the highest amount of distraction for physicians and cause the greatest amount of friction for patients in their journey with the physician enterprises. Those three tasks are clinical documentation, medical coding, and prior authorization. And again, happy to note that we created a set of interconnected agentic workflows that actually eliminate the friction associated with these tasks and relieve the provider's burden and distraction from these tasks. That was also something that was actually highlighted and recognized by Google a few months ago. In addition, we've also made very significant progress individually in these tasks. For example, again, Scribble Now, which is our fully autonomous ambient GenAI-enabled clinical documentation solution. We've also made significant progress in our autonomous coding solution that eliminates the burden of medical coding for our providers. And then similarly, we've actually launched a very, very state-of-the-art multi-agent orchestration model within our patient access module. And our patient access module consists of scheduling optimization, patient financial clearance, and also all of this is orchestrated by campaigns generated from our patient engagement hub. I also want to point out in this context, there's been a lot of news around things that people like Palantir and Anthropic are doing as it relates to code generation predominantly. I want to clarify that, look, more and more that these companies roll out tools that can make code generation faster and easier, the better it is for us. For example, we use Anthropic's leading platform, Claude, to actually do a lot of our code generation. And what it does is it collapses the development of the engineering cycle for us dramatically. Also, it allows our product managers, our technical product managers, to themselves be able to actually generate a lot of the code versus relying on heavy engineering talent to do that. So I think the propagation of these models from Anthropic and Palantir is a huge tailwind for us if we leverage those effectively, which we are certainly trying to do versus some people perceiving it as a potential headwind. And this is all predominantly driven by the fact that, remember, we are a business that wants to leverage technology to eliminate tasks. We don't care how the tasks are eliminated. The more we can eliminate through technology, the better it is. And so to the extent that these tools allow us to generate technology faster, cheaper, with a lower set of sophisticated talent, the better it is for us. So I think continued solid progress on our first vector of our strategy. The second vector is the acquisition that we did of AQuity back in 2023. I think it was November of 2023. Now that we are well past the two-year mark, happy to note that I think the integration is more or less complete. I think we're, as you have probably seen in our numbers, we have gotten the margins to the levels that we had felt we'll be able to get to, perhaps a bit faster than we had originally imagined that we'll be able to get to. And so I think that integration is more or less complete. The one vector that will continue to need work is the whole cross-sell motion into AQuity's health systems. And again, I'm very happy to note that as we sort of realigned our go-to-market engine with a very, very specific focus on the large health system segment and understanding what is the propensity to buy in that large health system segment, we are finally starting to see some real traction in that segment and in that cross-sell motion. So good early green shoots that are also obviously visible in some of our growth numbers give us confidence that we are in the final innings of the AQuity integration. I think perhaps another couple of quarters, and we are well on our way. We also, over the next couple of quarters, perhaps would have completed sort of the pruning of the long tail of customers that AQuity had, which is something that we've been doing thoughtfully over the last couple of years. So solid execution on that front. The third one, which is a very important strategic vector for our business look, I think what we all need to follow, our big thesis in the business, our right to win, is that you've invested in a business that has understood that in the medium to long term, large healthcare providers cannot be in the business of buying 16 different what I call features or point solutions and having 10, 12 different vendors that outsource these 16 point solutions for them. Eventually, everybody will start to realize that the value of the whole is greater than the sum of the individual parts. There will be a migration of buying behavior towards more and more platform vendor partners. We believe that we are probably today the most comprehensive platform player in the outpatient clinic setting. We are slowly building a similar platform for the hospital setting, which will take another couple of years. But in the outpatient setting, we're absolutely the number one in terms of the comprehensiveness of the platform. Yet, I think we've learned very carefully over the last several years that buying behaviors are different in different parts of the market. When you look at the large health system segment, which is where you're talking about systems greater than $5 billion, those systems today, even as they intellectually respond to the idea of the value of the full platform versus many point solutions, their buying behavior is still very point solution-oriented. So we've actually totally reinvented our go-to-market for that segment of the market as it relates to how we go to market. We will still introduce the idea of the platform, but we very quickly pivot to the construct of which point solutions can solve some of their immediate pain points. In these large systems, even the point solution wallets are so large that that strategy makes sense. That has been a strategic pivot that we've done. Having said that, what's also been interesting is the other segments of the market, mid to small health systems and standalone single specialty and multi-specialty physician groups. In those, there is a greater and greater proclivity to platform sales. That's really also where we're seeing some platform-based pickup. I think we've had four or five very significant platform sales since we went public over the last 18-odd months. And so a very, very cleanly stratified go-to-market between what the proclivity for platform is in the small to mid-size segment of the market and what the proclivity for point solutions is in the large health systems segment of the market. And then because we have to coexist in both of these buying behaviors, it behooves us to build this platform in a way where we are number one or two or three in each of these point solutions or features as rated by industry analysts, even as we are perhaps the only company with the footprint of the platform. And that execution is now starting to get demonstrated. The equivalent of the most followed analyst in our space, like it used to be Gartner in IT services, is this company called KLAS. And KLAS is an endeavor that we started maybe about 18-odd months ago. Happy to report that in two of our very, very significant features, clinical documentation and revenue cycle management, we are now starting to get rated as best in KLAS. So we've had some tremendous progress in the KLAS ratings, which gives us the confidence that our approach of striving to be leaders in each of the features, even as we are continuing to manifest the full platform, is gaining traction. Not an easy strategy to execute on, but we're steadfast on it. Then last but not the least, another very important differentiated execution pillar is this going further upstream and aligning our outcomes even more to our customers. As I had said earlier, traditionally, our outcome, our model with our customers has anyways been outcome-based where we get paid as a percentage of their revenue, not based on the number of people we deploy or the amount of technology we deploy. Right? Now, in this world, what we've done is, as you've heard from me over the last several quarters, we've gone further upstream and deployed a strategy where in a model that we, as we got more and more confidence that at the full deployment of our platform, the type of value we create for these healthcare enterprises is somewhere between, say, 700-1,000 basis points of EBITDA increase. Remember, these are basically 6%, 7%, 8% EBITDA business in the first place. If we can increase their EBITDA by 700-1,000 basis points by cutting their costs of these tasks and freeing up the doctor's time so that they can see more patients in that time that increases their revenue on the same fixed cost, you're talking about a value prop that can more than double the current EBITDA of this business. And remember, it's in an industry that is undergoing severe pressures because their reimbursement rates from insurance companies, both government and private insurance companies, are coming down, even though inflation is pretty strong in the U.S. So you have a business model that is under tremendous cost pressure. That is our customer's business model. And we have a business model that is able to fundamentally transform their margins that are today under tremendous pressure. It is with that belief that we have now started aligning further upstream and actually create a model where we have two streams of economics. One stream of economics is obviously at the deployment of our platform. The customers pay us the usage fee for basically eliminating those tasks. But the second pool of economics is where often we are incentivizing our customers to buy the full platform through what we call a Net Economic Value Add advance, which is nothing but a guarantee that we believe that will generate at least a certain amount of Net Economic Value Add. And truth be told, obviously, since this model is relatively new in the industry, many of you all were perhaps a little bit worried about is this approach going to work? I'm very, very happy to report that the first deal that we had done with a mid-size health system in Southern California called Palomar Health, in which we had advanced $16.5 million of net economic value add benefits to them in the first year itself, which, by the way, took us more than six months to implement the platform in the first place, maybe even close to eight months by the time the full platform was implemented. In the four months of full go-live, we've already been able to generate $3 million of net economic value add. So what was a 15-year contract for the full platform with this system, in which we had to recover $16.5 million, we've already created $3 million that we've been able to invoice for this last year. So it gives us a tremendous amount of confidence that the second pool of economics, beyond the traditional pool, which is the fees they pay us for the platform, the second pool of economics will actually turn out to be perhaps quite lucrative as well. Oh, by the way, all this is happening in a way where we have fundamentally transformed their patient experience, their physician experience, and their administrator experience and are starting to make them viable again. So I think I'm very, very happy to report the progress in this particular dimension. If we can continue to execute this across the four or five deals that we have done in this construct, I think it creates a totally transformative model for our business over a period of time. So all in all, a very strong quarter of execution as it relates to our five pillars, which, like I mentioned earlier, has also resulted in some recognition from KLAS that we are really happy about. And just to give a quick update, Saransh, if you can move to slide six. Just to give a quick update, I had spoken to you earlier about the 16 features that we have. And one of the things that we do is we constantly track the automation levels by feature. Now we are tracking actually two things. One, we are tracking the automation by feature. And second, we are tracking how many of these features are we starting to interconnect through agentic workflows. Because when you start to do that, actually, the value creation starts to get compounded across those features instead of being some of the parts. And again, happy to note, like I had said earlier, tremendous progress in the pre-visit section of our patient journey of our platform, where I was saying we've done these multi-agent orchestrations within optimized scheduling, patient financial clearance, and all of that campaign management through the patient engagement hub. Continued progress on taking Scribble just so that everybody follows the journey of each of these features. Most of them have started in a human-led and tech-in-the-loop. Then they go from tech-led, largely AI-led, to some human-in-the-loop because you always want some human-in-the-loop supervision. And then for some features, you can take them to such accuracy that you can also start to take them to full autonomy. And that is where, for example, we've achieved in Scribble Now, or for that matter, in autonomous coding, we're moving to full autonomy in a couple of specialties. As this journey manifests from human-led, tech-in-the-loop to tech-led, human-in-the-loop to full autonomy, you can see how the non-linearity in the business model plays out between revenue growth and people growth. So continued progress across these features. And all this has resulted in, like I was saying Saransh, you can move the slide to a very strong quarter of financial performance. Happy to note that in this quarter, we were able to grow our revenue to INR 815 crores, which is about a 24% year-on-year growth in revenue, 19% in constant currency terms. And we were able to do this while delivering some very strong EBITDA numbers. EBITDA came in at about INR 281 crores. Saransh, if you can go to slide nine, then we'll come back to the slide. EBITDA came in at INR 281 crores, which on a 24% revenue growth is an EBITDA growth of 40.4%. On a quarter-on-quarter basis, revenue grew 4.3% and EBITDA grew 3.6%. That's obviously, as you can imagine, there are some one-time impacts of the labor code changes, et cetera, which in our case are not that material for a multitude of reasons. But all of those factors are already baked into this EBITDA number of 35% and INR 281 crore. So there's no adjustments, et cetera, in this EBITDA, which all results in an overall PAT of INR 183 crore, which is actually a 41% year-on-year growth and 1.4% Q1Q growth. And there are a couple of non-cash items that are actually affecting the PAT. When you adjust for those non-cash items, actually, PAT comes to INR 215 crore, which is a 48% year-on-year growth and an 8.7% Q1Q growth. I'll let Nithya comment in her remarks about those non-cash adjustments. But overall, no matter how you look at it, a very, very strong quarter of financial performance, which, by the way, is really a byproduct of the team's working tirelessly to execute across our five pillars of execution. So with that, I'll turn it over to Nithya to dive into some of the more details of our financials, and we'll take it from there. Thank you, Sachin. Good morning, everyone. Taking off from Sachin's remarks on the numbers, I'll start with the one-off items that Sachin was referring to. There are two such items in the numbers this quarter. One is the labor code impact, though immaterial. It has been baked into the numbers. Second, we have refinanced our term loan this quarter. Investors will remember that we had assumed a term loan of almost $146 million at the time of acquiring AQuity. We, of course, continue to pay that down. We have now refinanced their term loan to a $50 million term loan. Of course, the refinancing triggered and accelerated amortization of the setup cost of the original loan. The INR 12.7 crore number is that one-time non-cash write-off, which is also sitting in the PAT numbers. Adjusted for these non-cash items, the PAT actually grew at almost 48%. We had about INR 215 crore of adjusted PAT this quarter. If we can go to the next slide, I'll cover a few more items. I think I'm missing the EPS slide, Saransh. Is that? Yeah. Just go to slide 10, Saransh. Yeah. Yeah. So EPS, of course, grew at a fairly healthy pace in line with our profit numbers. EPS grew to INR 11 in the quarter. It's a 40% year-on-year growth. Return on equity continues to be very healthy and was at 30% this quarter. Now again, adjusted for the one-offs I had highlighted earlier, this number is actually 33%. If we can go to the next one. We are in trouble moving the slides? Yeah. We're getting there. Yes. So cash generation continues to be very strong. If you look at the adjusted OCF and FCF numbers, conversion from EBITDA and PAT respectively continues to be very healthy and close to 100%. The actual OCF numbers, you need to adjust an INR 90 crore or $10 million number. This is towards an upfront performance guarantee that has been provided to a large customer. This will be booked as assets in our books, which will be recovered through the savings that we will be generating in our customer as we deploy our platform. If you look at the net debt numbers, again, it continues to come down. We ended the quarter at INR 322 crore or approximately $35 million in net debt. Saransh, if you can go to the next slide. Let's go to the summary financial slide. I think we've covered most of this. I have covered a lot of the highlights in my earlier remarks. I'll just call out a few additional callouts on this slide. You will note that forex gain in this quarter has been approximately INR 9 crore. But please note that we continue to maintain our hedging policy. And there is a INR 9 crore hedge loss that's also sitting in the revenue line item. So the currency impact has been net neutral for us this quarter. If you look at finance cost, this is where the INR 12.7 crore one-off write-off that I highlighted earlier is sitting. Adjusted for that number, our finance cost obviously continues to come down. And of course, with refinancing as well, we've got better interest rates. Moving down to tax, our ETR for the quarter was 20%. For the full year, please expect ETR to be around the same 21% number. If we can move to the next slide. So these are the standard set of KPIs that we report every quarter. Our EBITDA per employee number continues to be at a very, very healthy level and has grown substantially year-on-year, largely from the margin transformation that we have been able to achieve with the equity business model. Looking at the top 10 customers, top five customers, both of them have grown at a healthy pace, both year-on-year and quarter-on-quarter. And our vintage with both the top five customers and top 10 customers continues to be north of six years and fairly healthy. I'll end the prepared remarks here. And we are open to take questions now. Thank you, Nithya. Back to you all for questions. Thank you. Ladies and gentlemen, we will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on their touch-tone telephone. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use their handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. We take the first question from the line of Chirag Kachhadiya from Motilal Oswal Financial Services. Please go ahead. Hi. A couple of questions to Nithya and Sachin. So some of the deals which you mentioned in our investor presentation and in the five deals we shared with PPT, when they stick to start translating into the revenue, that is the question number one. Second, from the cost sale perspective, in the earlier deals which we announced in our earlier presentations of the earnings, what is the status of execution on those deals? And we repeatedly mentioned that near about 90% of revenue is coming from the same set of customers. So what is the incremental growth is coming from the deals so far disclosed post our listing? Yeah. So Chirag, I apologize. Not all aspects of your questions were clear. So I'll try to answer what I did here. I guess you were talking about the new deals that have been announced this quarter, which are Femwell, StrideCare, and then a couple of other deals where we can't name the customer. Are you looking for the potential revenue contribution from those? Because we don't generally give that specific deal by deal. So I will say that. I'm asking. Yeah. Please go ahead, Chirag. Yeah. So I'm asking if when these deals will get converted into revenue from which quarters? Yeah. So that's a good question. Two of those deals that are unnamed are actually kicking into Q4 itself. And the other two deals, Femwell and StrideCare, are expected to start kicking into revenue in Q1. StrideCare should go live entirely by the end of Q1, perhaps early Q2. The Femwell deal, which is their base of 800+ providers, is likely to go live across that 800 provider base over a six to nine month duration, starting in Q1. So it'll basically go from Q1 to Q3. Thank you. Are we only the sole provider of the services to these entities, or we are gaining a market share from the existing vendors? So on StrideCare, actually, Chirag, 90% of the time, we are replacing the incumbent, which is the in-house entity. So in the case of StrideCare, that is predominantly the case. They were using a tech vendor partially, which we are also replacing with our technology platform. In the case of Femwell, that is work that is typically being done by their doctors. And we are unburdening them of the clinical documentation work. And we will obviously be replacing their burdens and creating a whole bunch of net economic value add in that process. In the other two systems, we are not the sole provider. They are very large systems. One of them is one of the top five health systems in the country. And there, they use a combination of in-house teams as well as outsourced vendors like us. We are slowly moving to pole position as the outsourced partner for them. Just one more question. The revenues of this client, I mean, the deals which we have signed, what percentage of their operating expenses or overall revenue currently they are spending in these services, which provider like us can deliver them? Chirag, it's very hard to answer that generally because it's different for different customers. So I don't know how to give you an answer that applies across customers. But I will say that typically, our paradigm is that for sort of mid to large customers, on the revenue cycle, we tend to do end-to-end deals. So we often become their full wallet right at the get-go. For the very large health system, which is north of $5 billion, those are the ones that sort of grow incrementally over the period of time, no matter what the future may be, revenue cycle or clinical documentation or other features within clinical support or value-based care. So if the health system or the customer is greater than $5 billion in revenue, you should expect that we will land with one or more features and expand both those features and sell other features over a period of time. If it is a system that is, say, less than $1 billion or in that range, give or take, we tend to be in positions where we have a much more comprehensive commitment from the get-go. But it's very hard to generalize across the customer base. If the question is, is there still a large runway for selling into the existing customer base? The simple answer to that is absolutely yes. And we still continue to maintain that in most healthy growth years, somewhere between 85%-90% of our growth is going to come from existing customer expansion versus new customer addition. Thank you, Sachin, for the detailed explanation. Thank you. Thank you. We take the next question from the line of Ruchi Mukhija from ICICI Securities. Please go ahead. Thank you. Many congratulations on a strong quarter. A couple of questions. First, we saw press regarding U.S. administration's proposal to keep Medicare Advantage rate flat for next calendar year. So how would it impact demand for IKS? Could you help us understand that? Thank you for the question, Ruchi. Yes. Happy to do it. So look, I think if you really think about what that does, right, Medicare Advantage is a value-based care payment program that has bipartisan support in the U.S. And what they are doing is they are carefully recalibrating reinvestment for that program. Now, as they do that, it's going to put more pressure on the providers and/or risk-bearing entities that are enrolled in that program. Now, as that pressure increases, they are going to do everything they can to optimize both the cost of care provided to the patients within that program while optimizing the quality of care and also doing whatever they can to optimize the premium that they get for those lives within those set of lives that they are insured over. So the way to think about it is there are three levers that they have. They will want to optimize the premium that they get per life. They will try to reduce the cost of care associated with those lives so that they can make more margin between the premium increase and the reduced cost of care. And because the premium includes a kicker for delivering higher quality of care, they will want to improve the quality of care delivered. Now, when you think of our value-based care offerings for Medicare Advantage, they actually impact all of these three levers. How do you optimize premium? You optimize premium by appropriately capturing the risk associated with the condition of a patient. So for example, we have a large health system that we work with. And the Chief Medical Officer said, "When I look at how these patients that are at risk with me are coded, it shows that only 18% of my patients are obese. But when I talk to my doctors, they said at least 80% of the patients that they are seeing are obese. That means they are not accurately capturing the risk conditions of those patients, which then drive the premium they will get from Medicare. The more at risk the patient is, the better the premium is. So our service there of appropriately capturing risk per life becomes even more attractive for a system like this because the premiums are now under pressure. And the better you capture risk associated with the life or acuity associated with the life, the better your reinvestment is going to be. So that is as it relates to optimizing premium. And then we have services that allow these customers to not only provide better quality care but also report better quality care, which also improves their premium. And then last but not the least, within our value-based care portfolio, we have services that allow them to manage the total cost of care of these lives that they are insured under Medicare Advantage better. And those help improve the reduced cost. So when you really think about it, the more the pressure on these risk-bearing entities or providers, the more attractive our value-based care portfolio becomes to them. And so I fundamentally look at it as a macro tailwind for the value-based care business. Having said that, this space is very crowded. There are a lot of vendors. And so it's very important to my earlier comment that we emerge as one of the best players, the best vendor partners in value-based care, even as we have the full breadth of the platform so that as these risk-bearing entities are choosing who to partner with so that they can manage better in the new tighter environment, we emerge as their obvious choice. Thank you for that elaborate answer. Here, Sachin, in case a patient receives the care and the sum is not fully covered by insurance, does that result in loss of revenue, or does the patient have to pay out of pocket if the rate to revision is lower? So Ruchi, it's very hard to generalize that answer. It depends on what type of patient it is, right? If the patient is Medicaid eligible, then Medicaid would cover that patient, and you'd get reimbursed from Medicaid. If the patient wants to go out of pocket because there's super elite patients that even don't want to carry insurance, then that is a different rate that you get reimbursed by. And so I don't think there's a generic answer for what happens to the uninsured populations. But I will say that, look, in the end, we are representing the providers, right? And if the number of uninsured go up that are not able to pay for their care, what happens is the providers, which are our clients, their bad debt will go up. If their bad debt goes up, it puts more pressure on them. So I mean, I am so far not hearing any macro regulation that is not a fundamental tailwind for our business. Because the more and more the pressure, the more and more their proclivity to improve their margins and get providers operating at the top of their license by using platforms like us. Ruchi, just additional clarification that whatever you're hearing about Medicare Advantage doesn't mean that uninsured populations go up in the U.S. Yeah. There is no correlation between those two phenomena at all. The Medicare Advantage premiums are going to suffer unless the risk-bearing entities can justify better premiums to accurate risk capture. That will happen. But there is really no correlation between the MA premiums and the number of uninsured. Got it. Moving on, this quarter, we saw a very strong 25% revenue growth in your top six to 10 client bucket. Is this a reflection of Palomar and WWMG moving to this bucket? And could you help us? We did hear you talk about the net economic value generated in Palomar deal. How's the progress panning out on WWMG deal as well? Yeah. So thank you for the question, Ruchi. Look, I think what I don't want to get into is the paradigm of reporting progress on each deal. Having said that, the WWMG deal is absolutely on track. And we expect to see benefits being created over a period of time. And again, the results of the Palomar deal so far have given us a big shot in the arm and the confidence that this model has long-term sustainability. But it's still early days. And we'll see how it progresses in the future. Please understand one of the factors that drive the speed of the implementation of the full platform and the resulting net economic value add is also the underlying system of record or electronic health record that the customer has with whom we have to integrate our platform. Now, in the case of Palomar, they were on an electronic health record platform called NextGen, with whom we've had a longstanding relationship. And so we were perhaps able to integrate a bit faster, even though in spite of that relationship, it took us three months longer than we had hoped. In the case of Western Washington, they are on Epic. And that Epic is delegated to them through a large hospital in the area. So integration with Epic always takes longer than integration with other systems. And so things like those will always play into the specifics of each of these deal dynamics, Ruchi, which is why I don't know that the deal-specific nuances are of that much relevance. I think over a period of time, I think we have early indications that our fundamental thesis around this net economic value add model might turn out to be quite valuable. Okay. And as we report in our. Ruchi, I would request you to please join back the queue for follow-up questions. Sure. Thank you. We take the next question from the line of Prolin Nandu from Edelweiss Public Alternatives. Please go ahead. Yeah. Hi, team. Thank you for taking my question. Just to double-click on some of the previous participants' question on what is going on in the U.S., right, while the Medicaid inflation was lower than expected or price hikes, there are various cases of frauds which are also coming out in the provider mix, right, in maybe states of Florida and some other states as well. So while I appreciate your comment that in the longer term, all this is going to be positive for a platform like us, but in an interim, is there a risk that some of the volumes at our clients might suffer, right, because of whatever is going on? In the same context, how difficult is it to identify a consolidator client in such a scenario, right, where if I also think about your deal with Palomar, right, that also got acquired, right, in a very dynamic sort of a world, do you think that there could be some hiccups in our revenue before we probably realize the benefit of what is going on in the U.S. regulatory space? Thank you for the question. I think the answer is yes and yes. I mean, I'm sorry, but yeah. I mean, of course, this is a highly dynamic environment, also an environment where there is constant change in regulation. There is unpredictability of regulation. And then there is all this sort of need for buyers to discern the signal-to-noise ratio between AI hype and reality. And so in a world like this, if I stood here and said everything is a tailwind for us and everything will result in linear growth consistently quarter-on-quarter, year-on-year, I'd be lying. And so you're right. I mean, I don't know when the next hiccup is coming, which is why we don't give guidance. And that's why I keep saying that in general, if we are growing faster than 12%, we're gaining market share. If we're growing slower than 12%, we're losing market share. We're going to try to stick with that. We'll have some quarters where perhaps the numbers look better than other quarters, like this quarter that ended, Q3, which we are very proud of. Then there'll be other quarters where numbers will look worse. I don't think this is a mature, stable market where you can predict a linear growth curve quarter-over-quarter, year-over-year. If your question is, does this create unpredictability in the market, and could there be hiccups? Absolutely. I mean, hard for me to tell. I can just tell you that our clients are under more and more pressure. More and more pressure means that they have to do things that they haven't done in the past. Their pride of trying to own everything is definitely being tested right now. So that is a sort of macro fundamental trend that is undeniable. But how that plays out on a quarter-to-quarter basis, will there be some hiccups in some clients? Absolutely. Now, that only time will tell. So thank you. Yeah. Thank you, Sachin, for that. The second question is that you have done a fantastic job on margins, right? Part of it is coming because of the equity thing as well. In our kind of a business where 50% of our revenue is outcome-based, and we are moving towards a more platform deal and outcome-based deals as well, how should one think about ceiling on the margins or revenue per employee or EBITDA per employee? Because in a purely product company, right, every additional dollar of revenue comes at a very little marginal cost. In some of our outcome-based deal, is that something that will work out for us as well? So I think, look, we're not a pure product company, and we're not a pure services company, right? We still have 13,500 people nearly, which means that there are some tasks that are executed manually, and there are some tasks that technology is eliminating. What I will point you to is the fact that for 24% year-on-year growth, there has been 1.5% headcount growth. If you extrapolate this trend to the last five years, you'll see clear evidence of this trend. So it is not a one-year trend or a fluke phenomenon, right? So I think what you should continue to expect is more and more tech leverage in the business. But that more and more tech leverage will also get offset by continued expansion of R&D investment. As you've seen, our R&D investment this quarter is up to nearly 5%, 4.7%. I think it's about INR 39 crore, give or take. And so we intend to continue to expand our R&D investment in a world where everybody talks about AI. We're actually building AI and deploying it to make a real impact on patient lives, on provider lives, and in the process, on our bottom line. And so expansion of R&D investment also in a market where there is so much noise about the hype of AI, it's imperative that we continue to expand our marketing spends, which is going to be another level of investment. And then we'll continue to expand our sales force by market segment because each of the market segments are so nuanced and have their own dynamics. And so our stance between Nithya and me has always been that, look, once we get to early-to-mid 30s in margins, that is what you should expect from the business. We had thought we'd get there two quarters later. We got there two quarters sooner. I think we are in the range. And so I wouldn't model, if that's what you're looking to do, some significant margin expansion at the EBITDA level. Will we constantly keep trying to optimize gross margin? Yes. As we optimize gross margin, will we keep expanding our investments in SG&A, R&D, sales, and marketing? Yes. And we stay consistent with what we have said, is that this is the EBITDA range that we feel relatively comfortable with. And by that, I don't mean 35%, but this range within the next, say, 100-150 basis points. Thank you so much, Sachin, and all the very best. Thank you. Thank you. We take the next question from the line of Azeem from Barclays. Please go ahead. Yeah. Thank you. Congratulations on a good set of numbers. Question is around what we keep seeing on TV, right, this Anthropic and the way AI is progressing. I know you have covered enough. But still, the question that is lingering here is that how the competition is kind of matching up to your pace by using these agents and the way the entire Anthropic is disrupting SaaS and other areas. So what is that distinguished IP that you have which competition may not have when you're reaching out to your potential clients? So thank you for the question and for the kind words. I think the simple answer is this. Look, what is Anthropic? Anthropic has this platform called Claude. It's essentially a code generation platform. And it is a very sophisticated code generation platform where people that are not the most sophisticated engineers can actually rely on the platform to generate code. And it's very important for us to understand that we, as a business, are constantly writing code, leveraging AI to deploy this technology to eliminate task. As the Anthropics of the world keep making the Claudes of the world more and more sophisticated, we will be able to do more and more technology buildouts, hopefully at a lower cost, and deploy technology rapidly. So for us, we don't look nobody pays us to develop technology based on the number of people we deploy and all that, right? That's not our business model. So for companies that get paid because it takes 50 people to build a technology, Claude might now be able to do it with 14 people. And so obviously, they're going to run into headwinds. In our case, that is not the case at all. So I actually want more and more Claudes to come out, more and more Claudes software development kits to be rolled out so that we can accelerate our deployment cycle. Now, your next question as a corollary to that is, does that democratize the right for other new players to leverage these tools and also build a platform like us? And I think it'll be naive on my part to say that it doesn't. Yes, of course. Traditionally, what took us three years to build as a technology, today, we're building it in six months. So what is to say others won't build it? But please keep in mind, building the technology is one thing. Capturing market share is another. It has been 18 years that we have taken to capture 150,000 providers. We still face constant resistance working with our clients, convincing them to change what they are doing in spite of their pressures to penetrate, then integrating with their system of records, the EHRs. All of their clients, even when they're on an EHR, their data is in an absolute mess. So it takes a long time to get that data reorganized and vectorized so that these technology platforms can be effective with that data. So this notion that somehow these enterprises will leverage a tool like Claude and build all of these agentic workflows themselves is rather unrealistic, in my opinion. And so, look, I think we're hoping there's more and more Claudes, and there's more and more acceleration to the engineering cycle. And if in that process, some worthy competitors come in and create technology that is either better than ours or have a mousetrap that gets them into the market faster, all glory to them. Just keep in mind, it's a $260 billion TAM. Only $34 billion has been outsourced. We're under a $400 million company today. So look at the growth opportunity and the opportunity for multiple players to exist, which is why, as you can see, there is so much investment going in this space. And what are we doing in the middle of all that? We are trying to continue to drive industry-leading growth in a capital-efficient manner, not over-leveraging our balance sheet at all, and do deals that are fundamentally differentiated because we are doing more and more full-platform deals. I think welcome Anthropic and Palantir to bring more and more technology to benefit us. Thank you. We take the next question from the line of Dhaval Shah from Girik Capital. Please go ahead. Yeah. Hi, Dhaval Shah, right? Thank you for the opportunity. Great set of numbers. So my question is, am I audible? Hello? Yes, Dhaval. Absolutely. Hello? Yeah. Yes, Dhaval, you're very audible here. Thank you, sir. So in the second quarter call, we had discussed about getting this Epic EHR system integration, which was a big milestone for IKS. So I was just going through a couple of YouTube videos on Epic and all of that. So can you just help me understand the difference between what is this Epic product trying to offer, and what is the integration all about, and why is it a big milestone? You also mentioned that there's the other software called NextGen, I think, which the other providers are using, which will take a lesser time to integrate. So can you spend some time on this? What is this Epic, and what is the integration all about? Yeah, Dhaval, I'll try. But this is where I start getting accused of jargon. So I'm going to try. And then we're happy to talk to you because this is a very important question that deserves some real education. And if you don't mind reaching out to Saransh, we're happy to spend a good half an hour with you giving you details. But the way to think about this, Dhaval, is that in this space, there are two types there are three genres of companies that are competing for this $260 billion, three genres of companies. Forget about the in-house incumbents of these organizations. Let's leave them out for a second. The three external genres of companies are, one, system-of-record companies, which are the electronic health record vendors like Epic, Cerner, which is now called Oracle Healthcare, Athena, Allscripts, NextGen, eClinicalWorks. These are some of the major electronic health records, which are called systems of record because they were basically created to store longitudinal patient data. Traditionally, over the last 20 years, they've essentially been system of record. Now, with agentic AI coming in, traditionally, they were not in the business of eliminating tasks for these healthcare providers. In fact, they were creating more tasks because healthcare providers spent a lot of time and energy in managing these systems of record. Now, with agentic AI, they are starting to also want to get into the business of eliminating tasks by writing their own technology. What is their advantage? They are already incumbent in a customer. They already have all the data stored within their systems. And you need data to be able to orchestrate AI effectively in a customer's environment. So that is their advantage. The second genre of companies is what I call point solution system-of-actions, which are companies that just do clinical documentation, ambient AI companies like Abridge or DAX, which is owned by Microsoft, or Ambience. You've heard all these names, or companies that just do prior auth, or companies that just do patient access, which are individual one, two, three tasks within our overall platform. I call them point solution systems of action. Their idea was to eliminate actions that are unnecessary from the provider's environment. The third is what I call platform system of action, which are companies like us that have said point solutions are not the answer. System of action needs to be comprehensive and needs to eliminate all the chore tasks. So these three companies are fighting with each other for this $260 billion. The system of record, the Epic of the world, have an incumbent advantage because they're sitting in the customer's organization with data. We have an advantage because we're sitting in 150,000 providers already incumbent. We understand their workflows in detail like nobody else in the new world understands them. Now, how those dynamics will play out over a period of time, only time will tell. But my belief is there is enough market space for all three of these genres to succeed. I will make one distinction. I personally believe in the medium to long term, as valuations, etc., rationalize, there might be some coming together of system-of-record companies with system-of-action companies. If that coming together starts to happen, that might create the true 800-pound gorilla in this space. And so we are watching very carefully what's happening to these system-of-record companies. We are keeping our balance sheet healthy and strong. If some opportunities emerge, we will look to that. Until then, even though they are pseudo-competitors to us, we have to integrate with them because the data is coming from them, which is why integrating with Epic is a big deal. And the regulators, even though they realize that the system of action and system of record are competitors, are forcing the system of records to integrate with the system of action because they realize that they can't take the system of records can't take unfair advantage of their incumbency. So they still keep trying to take unfair advantage. Some play better ball with others. And over a period of time, slowly but surely, we are integrating with all of these. So hopefully, this gives you context. Happy to talk to you offline about this. This is a very important dynamic in our business. So just to add, I think, with respect to Epic, we're very happy that several of our proprietary technology products are now fully integrated into Epic. So if you look at Epic's showroom, you'll actually find our Scribble product, our Stacks product, and even a coding suite is now available on Epic. So what we mean is we're able to automatically integrate a product into Epic. We're able to read and write from Epic. And our products are able to work, therefore, in tandem with Epic. Got it. And my second question is, in the interest of time, the amount of cash which we are going to generate after we pay off the debt on the balance sheet. So of course, it'll be going towards your own business plus some inorganic. So now, the three segments which you just mentioned, so we will be looking for opportunities in all three of that, or which segment will be interesting to us at our size and the stage at which we are in the business cycle? Can you just throw some light on that as well? I think if there are some significant leaders in the point solution system of action in the health system market, those will be attractive. And then absolutely, system-of-record leaders in any of the segments of the market will be attractive. But like I said, the market has such hype on valuations right now. And we are generally pretty conservative. So we are going to be careful about it. But we'll absolutely keep our eyes and ears open. Got it. Nithya, what about the dividend policy? Do we have anything? Are we planning to have anything with this? I think, like Setsan pointed out, there are lots of opportunities. Are you able to still hear me? Hello? Yes, yes, very much. Yeah. I was saying that I can hear you. Yes, I can hear you. Hello? Yes. So we still have multiple opportunities to continue to grow our business as well as look at acquisition opportunities, which will be complementary to our business. Of course, the $50 million of debt that we still have is, of course, something that we want to pare that down pretty quickly. Those would be priorities in the near term. Got it. Okay. Thank you very much. Good luck. Thank you. We take the next question from the line of Abhishek Maheshwari from Skyridge Fund Managers. Please go ahead. Thank you for taking my question. So just two questions. First is regarding to what extent do we hedge our forex earnings? Because everything we earn is in dollars. So is it 100% hedging or a little less than that? It's 50%-60% of our net forex exposure. That's what we hedge. Only for the following 12 months? The second question is regarding 60% of the net forex exposure over the following 12 months. Understood. All right. So second question is regarding. I know you have already touched on it, but you've been growing very well last few years. Any concerns with respect to the base effect? Because, I mean, after a point, it does become difficult to grow at 30%-40% levels. So where are we in the cycle right now? Yeah. Look, I mean, as I've said, I think the market opportunity is large. Our simple thinking is if we grow faster than 12%, we're gaining market share. If we grow slower than 12%, we're losing market share. So far, we've been fortunate enough that we are able to drive that industry-leading growth. We believe that we have the wheels in motion to continue to try to do that. But again, I will warn everybody that nothing is linear in life. I think our base is still small enough relative to the size of the market, where growing faster than market is the headline. To me, that's the true definition of success in the market. The outsourced TAM is growing at 12%. So that's sort of how I think about it, even from the current base. This remark is based on the current environment, not the potential acquisitions you can make in the future, right? Yeah, that's right. All right. All right. Thank you so much. Thank you. We take the next question from the line of Jaip rakash Kumar from Korman Capital. Please go ahead. Yeah. I saw my question is on this platform. She talked about Claude and Palantir and all that. So right now, maybe they are kind of a subsidized low-cost, given that we use this comprehensive deal. Let's say if they increase the cost, how will it impact your cost base? Or is it just I understand maybe it's insignificant right now. But maybe in future, how significant it is in terms of usage and the cost? So look, I mean, in the end, there are two types of external technologies that we're using. We're using systems of compute, right? And we're using systems of logic. So these things like Claude, I would call them as systems of logic. I expect costs to fluctuate both in systems of compute and systems of logic. And hence, we continue to say that our R&D costs are likely to continue to inch up, not down, even as we continue to try and improve gross margins. And hence, our thought process is that please don't continue to model constant margin increases from these levels. So you should expect costs to perhaps increase over a period of time. But eventually, as you know very well, as technologies become more and more mainstream, adoption increases. Costs come down over a period of time. So it's going to be vola tile. That should be reflected in our R&D costs. We are anticipating that in our R&D costs. Thank you. Thank you. We take the next question from the line of Karan Shah from CWC Advisors. Please go ahead. Hi, Sachin. Good morning. I had a question around you have several qualitative factors that help us understand as investors, the medium to long-term growth drivers, the trajectory, and the opportunity that stands out in front of you. But quantitatively, what would be those granular metrics that you and your team hold yourself accountable to on a medium to long-term basis, apart from growing over and above your TAM rate? You see, thank you for the question. I mean, there are a whole bunch of metrics that we are holding ourselves accountable to internally that are driven by market segment. There are metrics by market segment. There are metrics by feature and feature cluster. Think about a metric like penetration of each feature in the customer's wallet, then penetration of number of features in a large enterprise customer. I mean, there are so many metrics by market segment and by feature and feature cluster that it would be hard to call those out on a call like this. But again, happy to discuss more of that offline. But obviously, as you can imagine, when you have such a full breadth of the platform and you're trying to execute full platform deals, and you're trying to execute individual point solution deals in certain segments of the market, the metrics differ by market segment and by feature cluster. And so I'm sorry, hard for me to sort of just enunciate them on this call. But just know that there are and those were the metrics just around revenue. Then there are metrics around margin. Then there are metrics around automation, like I discussed. How much is the human-led tech in the loop? When does it go from human-led tech in the loop to tech-led human in the loop, where humans become auditor of task versus doer of task? And then which features will get to autonomy when? What happens to the gross margin journey as the features go from human-led tech in the loop to tech-led human in the loop to full autonomy? So there's metrics around margin. Operating cash flows is one of the biggest metrics around which the whole leadership team is aligned. So again, sorry, but we have to actually head on out for a media interaction. But happy to talk to you more offline and give you more color on internal metrics. Maybe we can take. Are we done? Thank you. Yeah. I think we've asked them to just. Ladies and gentlemen, due to paucity of time, we take that as a last question. Further questions can be taken up with the IR team. I now hand the conference over to Mr. Saransh Mundra for his closing comments. Thank you. Thank you, everyone, for joining and asking all the questions. Really interactive session. I know we were not able to take some questions. Please feel free to reach out to me for any of those questions. Thank you again, everyone. Look forward to your continued support. Bye-bye. Thank you. Thank you. On behalf of ICICI Securities Limited, that concludes this conference call. Thank you for joining us. You may now disconnect your lines.